Cencora (NYSE:COR) Given New $292.00 Price Target at Robert W. Baird

Cencora (NYSE:COR) had its target price upped by stock analysts at Robert W. Baird from $287.00 to $292.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s price objective points to a potential upside of 17.03% from the stock’s current price.

Other analysts have also issued research reports about the stock. UBS Group increased their price objective on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. JPMorgan Chase & Co. upped their target price on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Bank of America reiterated a “neutral” rating and set a $245.00 price target (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Finally, Barclays upped their price objective on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $271.20.

Cencora Stock Performance

COR stock traded up $4.12 during midday trading on Thursday, reaching $249.50. The stock had a trading volume of 721,810 shares, compared to its average volume of 1,405,943. The firm has a fifty day simple moving average of $231.57 and a two-hundred day simple moving average of $230.64. Cencora has a 52-week low of $191.11 and a 52-week high of $250.43. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. The stock has a market cap of $49.16 billion, a PE ratio of 27.03, a P/E/G ratio of 1.49 and a beta of 0.44.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.21 by $0.13. The firm had revenue of $79.05 billion during the quarter, compared to analysts’ expectations of $77.68 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. As a group, equities research analysts anticipate that Cencora will post 13.64 EPS for the current year.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 15.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of COR. New Millennium Group LLC purchased a new position in Cencora during the second quarter worth approximately $26,000. TCTC Holdings LLC purchased a new position in shares of Cencora during the 1st quarter worth $29,000. TFO Wealth Partners LLC acquired a new position in shares of Cencora during the 1st quarter valued at about $30,000. LRI Investments LLC acquired a new stake in Cencora during the first quarter worth about $31,000. Finally, MFA Wealth Advisors LLC acquired a new stake in Cencora during the second quarter worth about $30,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.